Ganciclovir showed no clear difference in acute rejection compared with aciclovir (high certainty).
Ganciclovir showed no clear difference in graft loss compared with aciclovir (moderate certainty).
Ganciclovir showed no clear difference in opportunistic infections: other viral infections compared with aciclovir (moderate certainty).
Ganciclovir may leads to higher leucopenia compared with aciclovir (low certainty).
Ganciclovir showed no clear difference in kidney dysfunction compared with aciclovir (moderate certainty).
Valaciclovir showed no clear difference in CMV disease compared with ganciclovir or valganciclovir (low certainty).
Valaciclovir showed no clear difference in all‐cause death compared with ganciclovir or valganciclovir (low certainty).
Valaciclovir showed no clear difference in CMV infection compared with ganciclovir or valganciclovir (low certainty).
Antiviral prophylaxis probably leads to lower death due to CMV disease compared with placebo or no treatment (moderate certainty).
It is very uncertain whether valaciclovir changes acute rejection compared with ganciclovir or valganciclovir (very low certainty).
Valaciclovir showed no clear difference in graft loss compared with ganciclovir or valganciclovir (low certainty).
Valaciclovir showed no clear difference in leucopenia compared with ganciclovir or valganciclovir (moderate certainty).
Extended probably leads to lower CMV disease compared with short‐duration valganciclovir (moderate certainty).
Extended showed no clear difference in all‐cause death compared with short‐duration valganciclovir (low certainty).
Extended probably leads to lower CMV syndrome compared with short‐duration valganciclovir (moderate certainty).
Extended may leads to lower CMV infection compared with short‐duration valganciclovir (low certainty).
Extended probably leads to lower acute rejection compared with short‐duration valganciclovir (moderate certainty).
Extended showed no clear difference in opportunistic infections compared with short‐duration valganciclovir (low certainty).
Antiviral prophylaxis leads to lower all‐cause death compared with placebo or no treatment (high certainty).